
Angiogenesis, the Sequel: Does Cyramza (Ramucirumab) Make a Difference for Second Line Treatment?
0:00
7:28
The REVEL trial studied 1,200 non-small cell lung cancer patients to see if the drug Cyramza (ramucirumab) improved overall surival. The doctors had mixed feelings about the results.
Otros episodios de "GRACEcast Social Work and Coping Audio"



No te pierdas ningún episodio de “GRACEcast Social Work and Coping Audio”. Síguelo en la aplicación gratuita de GetPodcast.








